1. Home
  2. RCEL vs BRW Comparison

RCEL vs BRW Comparison

Compare RCEL & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • BRW
  • Stock Information
  • Founded
  • RCEL 2020
  • BRW 1987
  • Country
  • RCEL United States
  • BRW United States
  • Employees
  • RCEL N/A
  • BRW N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • BRW Trusts Except Educational Religious and Charitable
  • Sector
  • RCEL Health Care
  • BRW Finance
  • Exchange
  • RCEL Nasdaq
  • BRW Nasdaq
  • Market Cap
  • RCEL 310.6M
  • BRW 321.5M
  • IPO Year
  • RCEL N/A
  • BRW N/A
  • Fundamental
  • Price
  • RCEL $12.87
  • BRW $7.57
  • Analyst Decision
  • RCEL Hold
  • BRW
  • Analyst Count
  • RCEL 3
  • BRW 0
  • Target Price
  • RCEL $16.50
  • BRW N/A
  • AVG Volume (30 Days)
  • RCEL 112.9K
  • BRW 222.1K
  • Earning Date
  • RCEL 11-07-2024
  • BRW 01-01-0001
  • Dividend Yield
  • RCEL N/A
  • BRW 15.59%
  • EPS Growth
  • RCEL N/A
  • BRW N/A
  • EPS
  • RCEL N/A
  • BRW N/A
  • Revenue
  • RCEL $60,040,000.00
  • BRW N/A
  • Revenue This Year
  • RCEL $34.73
  • BRW N/A
  • Revenue Next Year
  • RCEL $54.61
  • BRW N/A
  • P/E Ratio
  • RCEL N/A
  • BRW N/A
  • Revenue Growth
  • RCEL 32.24
  • BRW N/A
  • 52 Week Low
  • RCEL $7.51
  • BRW $7.15
  • 52 Week High
  • RCEL $18.93
  • BRW $8.30
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 64.34
  • BRW 61.15
  • Support Level
  • RCEL $11.63
  • BRW $7.50
  • Resistance Level
  • RCEL $13.82
  • BRW $7.56
  • Average True Range (ATR)
  • RCEL 0.86
  • BRW 0.05
  • MACD
  • RCEL 0.09
  • BRW 0.00
  • Stochastic Oscillator
  • RCEL 74.46
  • BRW 80.56

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund t is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

Share on Social Networks: